Angle PLC 2024 AR2
The report highlights ANGLE plc's commercial and technical progress in 2024, particularly in securing contracts with large pharmaceutical companies like Eisai and AstraZeneca for its Parsortix liquid biopsy system. Despite challenging market conditions and a global slowdown in research funding, the company streamlined its operations to focus on these high-value pharma partnerships. Financially, ANGLE reported revenues of £2.9 million, up 31% from the previous year, and successfully completed a £9.3 million fundraising round to support strategic growth. The company also advanced its next-generation sequencing workflows for dual analysis of CTC-DNA and ctDNA, positioning itself for future expansion.
Company: Angle PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2024
Type: AR2
Pages: 134
Angle PLC
The report highlights ANGLE plc's commercial and technical progress in 2024, particularly in securing contracts with large pharmaceutical companies like Eisai and AstraZeneca for its Parsortix liquid biopsy system. Despite challenging market conditions and a global slowdown in research funding, the company streamlined its operations to focus on these high-value pharma partnerships. Financially, ANGLE reported revenues of £2.9 million, up 31% from the previous year, and successfully completed a £9.3 million fundraising round to support strategic growth. The company also advanced its next-generation sequencing workflows for dual analysis of CTC-DNA and ctDNA, positioning itself for future expansion.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees